Bio Plus Co

Bio Plus Co Operating Expenses

The Total Operating Expenses of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 25.80 B KRW. In the previous year, Total Operating Expenses was 17.51 B KRW — a change of 47.34% (higher).

Operating Expenses

25.80 BKRW

YoY

47.34%

Last updated:

Total Operating Expenses of Bio Plus Co is 2025 25.80 B KRW. Total Operating Expenses of Bio Plus Co was 2024 17.51 B KRW. It decreases by 47.34% higher compared to the previous year.

The Bio Plus Co Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
2.69 B KRW
Jan 1, 2019
3.65 B KRW
Jan 1, 2020
4.07 B KRW
Jan 1, 2021
5.07 B KRW
Jan 1, 2022
7.77 B KRW
Jan 1, 2023
10.57 B KRW
Jan 1, 2024
17.51 B KRW
Jan 1, 2025
25.80 B KRW
The Bio Plus Co Operating Expenses history
YEAROperating ExpensesYoY
25.80 BKRW+47.34%
17.51 BKRW+65.65%
10.57 BKRW+36.09%
7.77 BKRW+53.15%
5.07 BKRW+24.72%
4.07 BKRW+11.52%
3.65 BKRW+35.77%
2.69 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Total Operating Expenses of Bio Plus Co is 25.80 B KRW in 2025.

Total Operating Expenses of Bio Plus Co changed from 17.51 B KRW to 25.80 B KRW, representing a 47.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Bio Plus Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bio Plus Co

All Key Metrics — Bio Plus Co